D.Western Therapeutics Institute,Inc.is a biotechnology company that focuses on development of innovative new drags to serve patients worldwide.

DW-1002

DW-1002

We had acquired of business relating to an ophthalmic surgical adjuvant containing BBG250 with Healios K.K. in April 30, 2017.
BBG250 is a pigment having high staining properties, discovered by the research group at Kyushu University. Based on an exclusive license from Kyushu TLO Co., Ltd., Healios K.K. has been developed an ophthalmic surgical adjuvant that uses this pigment as the primary ingredient.

Clinical indication : ILM peeling

Development stage Launched
Market Europe
License out to Dutch Ophthalmic Research Center International B.V. (DORC)
Overview We has granted an exclusive, worldwide sublicense, other than Japan, of the ophthalmic surgical adjuvant mentioned above, to DORC. DORC produces and has been selling the surgical adjuvant in the EU since September 2010 as a product compliant with EU safety standards and displaying the CE marking.

ILM-Blue

【“ILM Blue” – a product sold in the EU by DORC】

Clinical indication : ILM peeling

Development stage Phase III trial
Market USA
License out to Dutch Ophthalmic Research Center International B.V. (DORC)
Overview We has granted an exclusive, worldwide sublicense, other than Japan, of the ophthalmic surgical adjuvant mentioned above, to DORC.

Clinical indication : ILM staining

Development stage Phase III trial
Market Japan
License out to Wakamoto Company, Ltd.
Overview We have granted an exclusive sublicense of an inner liming membrane stain for use in ophthalmic surgeries to Wakamoto Company, Ltd. and phase III trial was completed in Japan. Currently, development is under way at Wakamoto towards obtaining the product’s manufacturing and marketing approval.

Clinical indication : Cataract surgery

Development stage Phase III trial
Market Japan
License out to -
Overview At Kyushu University Hospital, investigator initiated clinical trials are taking place. We are working on licensing out.

Feature of DW-1002

The product is a new ophthalmic surgical adjuvant, which has been developed using a dye with high stainability discovered by a research team at Kyushu University and contains Brilliant Blue G-250 as the primary component. The product makes use of the high stainability of BBG250 to safely stain the intraocular inner limiting membrane, to facilitate the peeling of the membrane during ophthalmic surgeries.

 

PAGETOP
D.Western Therapeutics Institute, Inc.
1-18-11, Nishiki, Naka-ku,
Nagoyashi, Aichi 460-0003 Japan
TEL 81+52-218-8785
Copyright © D.Western Therapeutics Institute, Inc. All Rights Reserved.